LaSalle Street Capital Management LLC increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 21.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,319 shares of the medical research company’s stock after purchasing an additional 944 shares during the period. LaSalle Street Capital Management LLC’s holdings in Charles River Laboratories International were worth $575,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Alps Advisors Inc. raised its holdings in Charles River Laboratories International by 0.3% during the second quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock worth $541,000 after purchasing an additional 14 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Charles River Laboratories International by 0.5% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,953 shares of the medical research company’s stock worth $703,000 after purchasing an additional 33 shares in the last quarter. Bbva Compass Bancshares Inc. raised its holdings in Charles River Laboratories International by 0.8% during the second quarter. Bbva Compass Bancshares Inc. now owns 6,004 shares of the medical research company’s stock worth $607,000 after purchasing an additional 50 shares in the last quarter. World Asset Management Inc raised its holdings in Charles River Laboratories International by 2.2% during the second quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock worth $279,000 after purchasing an additional 59 shares in the last quarter. Finally, M&T Bank Corp raised its holdings in Charles River Laboratories International by 1.8% during the second quarter. M&T Bank Corp now owns 4,358 shares of the medical research company’s stock worth $441,000 after purchasing an additional 76 shares in the last quarter. 97.46% of the stock is owned by hedge funds and other institutional investors.

CRL has been the subject of several analyst reports. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. BidaskClub cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Robert W. Baird reaffirmed a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a report on Friday, September 1st. Jefferies Group LLC reaffirmed a “buy” rating and issued a $120.00 target price on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Finally, Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 target price for the company. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $106.63.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) traded down $0.08 on Friday, hitting $101.39. 367,205 shares of the stock were exchanged, compared to its average volume of 514,005. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. Charles River Laboratories International, Inc. has a fifty-two week low of $69.51 and a fifty-two week high of $119.05. The stock has a market cap of $4,802.03, a PE ratio of 19.92, a price-to-earnings-growth ratio of 1.62 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The business had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. During the same period last year, the company posted $1.18 EPS. The company’s revenue was up 9.0% on a year-over-year basis. equities analysts expect that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/19/lasalle-street-capital-management-llc-has-575000-position-in-charles-river-laboratories-international-inc-crl.html.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total transaction of $678,150.00. The disclosure for this sale can be found here. Over the last three months, insiders have bought 10,500 shares of company stock valued at $2,885 and have sold 1,012,147 shares valued at $1,591,514. Company insiders own 2.20% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.